Every Form 4 that Precision BioSciences, Inc. (DTIL) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow DTIL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full DTIL filings page.
Precision Biosciences, Inc. (DTIL) director Stanley Frankel purchased 1,000 shares of common stock directly on September 28, 2026, at $6 per share. The transaction is described as a purchase in the open market or a private transaction. Afterward, Frankel directly held 41,478 shares. No Rule 10b5-1 plan is reported.
Precision Biosciences Inc. (DTIL) director Melinda Brown purchased 1,135 shares of common stock at $6.27 per share on September 25, 2026. The purchase was reported as an open-market or private transaction. Her directly held position afterward was 45,481 shares, and no Rule 10b5-1 plan is reported.
Precision BioSciences (DTIL) director Geno J. Germano purchased 2,609 shares of common stock on September 25, 2026, at $6.28 per share. The transaction is described as a purchase in the open market or a private transaction. The shares were held directly, and his reported direct holdings after the purchase were 47,492 shares. No Rule 10b5-1 plan is reported.
Brown Melinda reported acquisition or exercise transactions in this Form 4 filing.
PRECISION BIOSCIENCES INC director Melinda Brown received a grant of 20,979 restricted stock units (RSUs) tied to common stock. Each RSU represents a right to receive one share of common stock. The RSUs vest on the earlier of June 3, 2027, or the day before the company’s next annual stockholder meeting following the grant date, assuming she continues serving the company through that vesting date. After this grant, she holds 20,979 RSUs directly.
Frankel Stanley reported acquisition or exercise transactions in this Form 4 filing.
PRECISION BIOSCIENCES INC director Stanley Frankel received a grant of 20,979 restricted stock units. Each RSU represents a contingent right to one share of common stock. The RSUs vest on the earlier of June 3, 2027 or the day before the next annual stockholder meeting, subject to his continued service.
Germano Geno J reported acquisition or exercise transactions in this Form 4 filing.
PRECISION BIOSCIENCES INC director Geno J. Germano received a grant of 20,979 restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the company’s common stock. The RSUs vest on the earlier of June 3, 2027 or the day immediately before the next annual stockholders’ meeting following the grant date, subject to his continued service with the company.
Pire Shari Lisa reported acquisition or exercise transactions in this Form 4 filing.
PRECISION BIOSCIENCES INC director Shari Lisa Pire received a new equity grant. She was awarded 20,979 restricted stock units (RSUs), each representing a right to receive one share of the company’s common stock if vesting conditions are met.
The RSUs vest on the earlier of June 3, 2027 or the day immediately before the company’s next annual stockholder meeting following the grant date, provided she continues serving the company through that vesting date. After this grant, she holds 20,979 RSUs directly.
Buehler Kevin reported acquisition or exercise transactions in this Form 4 filing.
PRECISION BIOSCIENCES INC director Kevin Buehler received a grant of 20,979 Restricted Stock Units (RSUs), each representing a contingent right to one share of common stock. These RSUs vest on the earlier of June 3, 2027, or the day immediately before the company’s next annual stockholder meeting, subject to his continued service. Following this compensation-related award, Buehler holds 20,979 RSUs directly.
PRECISION BIOSCIENCES INC Chief Research Officer J. Jefferson Smith received a grant of 57,389 Restricted Stock Units. Each unit represents a contingent right to receive one share of common stock, so this award could convert into 57,389 shares if fully vested.
The RSU award vests in three substantially equal annual installments beginning on February 19, 2027, conditioned on Smith’s continued service with the company through each vesting date. Following this grant, Smith’s reported derivative holdings from this award total 57,389 RSUs, reflecting a compensation-related equity grant rather than an open-market purchase or sale.
Scimeca Dario reported acquisition or exercise transactions in this Form 4 filing.
PRECISION BIOSCIENCES INC reported that its General Counsel and Secretary, Dario Scimeca, received a grant of 107,604 restricted stock units. Each unit represents a contingent right to receive one share of the company’s common stock at no purchase price.
The award vests in three substantially equal annual installments beginning on February 18, 2027, conditioned on his continued service with the company through each vesting date. Following this grant, he holds 107,604 restricted stock units directly.
PRECISION BIOSCIENCES INC reported that Chief Financial Officer Kelly John Alexander received a grant of 193,688 Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of common stock at no exercise price. The award vests in three substantially equal annual installments beginning on February 19, 2027, conditioned on his continued service with the company through each vesting date. Following this grant, he is reported as holding 193,688 RSUs directly.
Amoroso Michael reported acquisition or exercise transactions in this Form 4 filing.
PRECISION BIOSCIENCES INC President and CEO Michael Amoroso reported a compensation-related equity grant. He received 573,888 Restricted Stock Units, each representing a contingent right to receive one share of the company’s common stock. The award vests in three substantially equal annual installments beginning on February 18, 2027, conditioned on his continued service with the company. Following this grant, his reported holding of these RSUs is 573,888 units.
PRECISION BIOSCIENCES INC director Kevin Buehler reported the vesting and settlement of restricted stock units into common shares. On May 20, 2026, 21,000 RSUs converted into 21,000 shares of common stock at no cash exercise price. These RSUs were granted on June 3, 2025 and vested based on continued service. Following this equity award vesting, Buehler directly owns 49,137 shares of common stock and did not report any share sales in this filing.
PRECISION BIOSCIENCES INC director Stanley Frankel reported the vesting of equity awards, rather than an open-market trade. On May 20, 2026, 21,000 Restricted Stock Units (RSUs) converted into the same number of shares of common stock at an exercise price of $0.00 per share.
These RSUs were originally granted on June 3, 2025 and vested based on continued service and the timing of the company’s next annual stockholders’ meeting. Following this vesting event, Frankel directly holds 40,478 shares of Precision BioSciences common stock. The filing does not show any same-day sale of these shares, so this appears to be a routine compensation-related equity vesting and exercise.
PRECISION BIOSCIENCES INC director Melinda Brown acquired 21,000 shares of Common Stock through RSU vesting. On May 20, 2026, 21,000 Restricted Stock Units converted into the same number of common shares at a price of $0.00 per share, reflecting equity compensation rather than a market purchase.
Each RSU provided a contingent right to receive one share of common stock, based on an award granted on June 3, 2025. Following this vesting event, Brown directly holds 44,346 common shares. No shares were sold, gifted, or withheld for taxes in this filing.
PRECISION BIOSCIENCES INC director Shari Lisa Pire reported a compensation-related share acquisition. On May 20, 2026, 21,000 Restricted Stock Units vested and were settled into 21,000 shares of Common Stock. No sale was reported, and she now directly holds 35,028 Common Shares.
The RSUs were originally granted on June 3, 2025 and were scheduled to vest on the earlier of June 3, 2026 or the day before the next annual stockholder meeting, subject to her continued service. Each RSU represented the right to receive one share of Common Stock upon vesting.
Germano Geno J reported acquisition or exercise transactions in this Form 4 filing.
PRECISION BIOSCIENCES INC director Germano Geno J reported a routine equity compensation event. On May 20, 2026, 21,000 Restricted Stock Units vested and were settled into 21,000 shares of Common Stock at a price of $0.00 per share. Following this vesting, he directly holds 44,883 shares of Common Stock. The RSUs were originally granted on June 3, 2025 and were scheduled to vest on the earlier of June 3, 2026 or the day immediately before the company’s next annual stockholders’ meeting, subject to continued service.
Precision BioSciences President and CEO Michael Amoroso reported a mix of RSU vesting and a tax-related share sale. On February 17, 2026, 67,797 Restricted Stock Units vested, with each RSU converting into one share of common stock. On February 18, 2026, he sold 20,559 common shares at $3.84 per share in an open-market transaction executed under a pre-arranged Rule 10b5-1 plan, solely to cover tax withholding and related fees from the RSU vesting. Following these transactions, he directly held 243,392 shares of common stock and 135,593 RSUs, which continue to vest in three substantially equal annual installments beginning February 17, 2026, contingent on continued service.
Precision Biosciences Chief Financial Officer John Alexander reported RSU vesting and related share transactions. On February 17, 2026, 27,584 Restricted Stock Units vested, each representing a right to receive one share of common stock, and were settled into 27,584 common shares at a stated price of $0.00 per share.
On February 18, 2026, he sold 8,149 common shares at $3.84 per share in an open-market transaction executed under a Rule 10b5-1 trading plan. According to the footnotes, this was a sell-to-cover transaction, with shares sold only to satisfy tax withholding and related fees from the RSU vesting.
After these transactions, he directly held 125,883 shares of common stock and 55,166 RSUs, with the RSUs scheduled to vest in three substantially equal annual installments beginning on February 17, 2026, subject to his continued service with the company.
PRECISION BIOSCIENCES INC General Counsel and Secretary Dario Scimeca reported RSU vesting and a related tax sale of common stock. On February 17, 2026, 16,667 Restricted Stock Units vested and converted into 16,667 shares of common stock, increasing his direct holdings. Each RSU represents a right to receive one common share.
On February 18, 2026, he sold 4,925 common shares in an open-market transaction at $3.84 per share under a pre-established Rule 10b5-1 trading plan. The sale was a "sell-to-cover" transaction, with shares sold only to cover tax withholding obligations and related fees from the RSU vesting.
Precision BioSciences Chief Research Officer J. Jefferson Smith reported RSU vesting and a related tax sale of common stock. On February 17, 2026, 16,667 Restricted Stock Units vested, each representing one share of common stock, as part of an award scheduled to vest in three equal annual installments beginning on that date.
In connection with this vesting, on February 18, 2026 he executed an open-market sell-to-cover of 4,925 common shares at $3.84 per share under a pre-established Rule 10b5-1 plan, solely to satisfy tax withholding and related fees. After these transactions, he directly held 121,926 common shares and 33,333 RSUs, with an additional 7,931 common shares held indirectly through a charitable remainder unitrust.
Precision BioSciences President and CEO Michael Amoroso reported routine equity activity tied to vesting of restricted stock units (RSUs) and related tax withholding. On January 20, 2026, RSUs covering 8,888, 37,069, and 69,421 shares vested and were converted into an equal number of common shares.
On January 22, 2026, Amoroso sold 34,799 shares of common stock at a weighted average price of $4.17 per share, in multiple trades between $3.97 and $4.30. The filing states these sales were made under a pre-arranged Rule 10b5-1 plan and were solely to cover tax withholding and fees from the RSU vesting. After these transactions, he directly held 196,154 common shares, plus 37,069 and 69,421 unvested RSUs.
Precision BioSciences (DTIL) reported insider equity activity by its General Counsel and Secretary, Dario Scimeca. On January 20, 2026, several tranches of Restricted Stock Units (RSUs) vested, resulting in the issuance of 1,978, 8,425 and 14,908 shares of common stock at an exercise price of $0 per share. These RSUs were granted in 2023 and 2024 and vest in three substantially equal annual installments, subject to continued service.
On January 21, 2026, Scimeca sold 8,854 shares of Precision BioSciences common stock at $4.03 per share in a transaction coded as a sale. According to the disclosure, this was a Rule 10b5-1 sell-to-cover transaction, with shares sold only to satisfy tax withholding and related fees arising from the RSU vesting. After these transactions, Scimeca directly held 44,715 shares of common stock.
Precision BioSciences Chief Financial Officer John Alexander Kelly reported routine equity compensation activity. On January 20, 2026, previously granted Restricted Stock Units vested, resulting in the delivery of 3,888, 13,900, and 26,575 shares of common stock, each RSU converting into one share. On January 21, 2026, Kelly sold 15,213 shares of common stock at $4.03 per share under a pre-established Rule 10b5-1 trading plan. The sale was a sell-to-cover transaction, with shares sold only to cover tax withholding obligations and related fees tied to the RSU vesting. After these transactions, Kelly directly held 106,448 shares of Precision BioSciences common stock.
Precision BioSciences Chief Research Officer J. Jefferson Smith reported RSU vesting and a related tax sale. On January 20, 2026, RSUs covering 2,500, 10,447, and 16,219 shares vested, each RSU representing one share of common stock. On January 21, 2026, Smith sold 10,200 shares of common stock at $4.03 per share under a pre-arranged Rule 10b5‑1 plan as a sell‑to‑cover transaction for tax withholding tied to the RSU vesting.
Following these transactions, Smith directly owned 110,184 shares of Precision BioSciences common stock and held an additional 7,931 shares indirectly through a charitable remainder unitrust. RSU holdings after the transactions included 10,447 and 16,219 units that remain subject to their vesting schedules.
Precision Biosciences Inc. director Geno Germano reported an open-market purchase of the company’s common stock. On 12/16/2025, he bought 3,000 shares of common stock at a weighted average price of $4.72 per share, with individual trade prices ranging from $4.718 to $4.720.
Following this transaction, Germano beneficially owns 23,883 shares of Precision Biosciences common stock in direct ownership.
Precision BioSciences director Stanley R. Frankel reported buying 2,700 shares of the company’s common stock on December 16, 2025 at a price of $4.70 per share. This insider purchase increased his directly held stake to 19,478 shares. The transaction was reported as a routine filing by a single reporting person.
Precision BioSciences director Melinda Brown reported buying 1,381 shares of the company’s common stock on 12/15/2025 at a weighted average price of $4.97 per share. Following this open-market purchase, she beneficially owns 23,346 shares held directly. The shares were acquired in multiple transactions at prices ranging from $4.95 to $5.01, and the reporting person has undertaken to provide full trade-level pricing details upon request.
Precision BioSciences (DTIL) reported insider activity by CFO John Alexander Kelly. On November 2, 2025, 3,605 RSUs vested and settled, resulting in the acquisition of 3,605 common shares at $0. On November 3, 2025, he sold 1,303 shares at $6.49 under a Rule 10b5-1 plan as a sell-to-cover for tax withholding tied to the RSU vesting. Following these transactions, he beneficially owns 77,298 shares.
Precision BioSciences (DTIL) reported an insider transaction by General Counsel and Secretary Dario Scimeca on a Form 4. On November 2, 2025, 1,835 RSUs vested (code M) and converted into common stock at $0. On November 3, 2025, 665 shares were sold at $6.49 in a sell-to-cover for taxes under a Rule 10b5-1 plan adopted September 29, 2025. Following these transactions, the reporting person beneficially owned 28,258 shares directly. The holdings figure includes 2,088 shares acquired via the 2019 ESPP at a weighted average price of $4.26.
Precision BioSciences (DTIL) reported an insider equity transaction by President & CEO and Director Michael Amoroso. On November 2, 2025, 9,444 RSUs vested and settled into common stock at $0 per unit, reflecting standard RSU settlement mechanics.
On November 3, 2025, Amoroso sold 3,409 shares at $6.49 per share under a Rule 10b5-1 plan adopted on August 2, 2024. The filing states this was a sell-to-cover transaction to satisfy tax withholding tied to the RSU vesting. Following these transactions, Amoroso beneficially owned 115,575 shares directly. No derivative securities remained after settlement.